Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Assets Average (2016 - 2025)

Spyre Therapeutics' Assets Average history spans 10 years, with the latest figure at $641.2 million for Q4 2025.

  • For Q4 2025, Assets Average rose 24.56% year-over-year to $641.2 million; the TTM value through Dec 2025 reached $641.2 million, up 24.56%, while the annual FY2025 figure was $693.1 million, 45.87% up from the prior year.
  • Assets Average reached $641.2 million in Q4 2025 per SYRE's latest filing, up from $521.7 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $641.2 million in Q4 2025 to a low of $61.8 million in Q1 2023.
  • Average Assets Average over 5 years is $289.2 million, with a median of $194.0 million recorded in 2021.
  • Peak YoY movement for Assets Average: tumbled 40.63% in 2022, then skyrocketed 571.1% in 2024.
  • A 5-year view of Assets Average shows it stood at $119.5 million in 2021, then tumbled by 31.92% to $81.4 million in 2022, then soared by 237.49% to $274.6 million in 2023, then skyrocketed by 87.49% to $514.8 million in 2024, then increased by 24.56% to $641.2 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Assets Average are $641.2 million (Q4 2025), $521.7 million (Q3 2025), and $554.3 million (Q2 2025).